ArticleJournal of the Society for Cardiovascular Angiography & Interventions2024
Mechanical Thrombectomy for High-Risk Pulmonary Embolism: Insights From the US Cohort of the FLASH Registry.
Article in Journal of the Society for Cardiovascular Angiography & Interventions, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03761173 (FlowTriever All-Comer Registry for Patient Safety and Hemodynamics), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
FlowTriever All-Comer Registry for Patient Safety and Hemodynamics (FLASH)
Who cites it
12 citing papers in PubMed.
- Aspiration Thrombectomy in High-Risk Pulmonary Embolism: Mechanical Reperfusion for Thrombosed Arteries Proven Again.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
- Outcome of Patients Presenting With High-Risk Pulmonary Embolism Treated With Mechanical Thrombectomy: A Subgroup Analysis From the STRIKE-PE Study.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
- Imaging-Driven Risk Stratification and Endovascular Decision Pathways in Acute Pulmonary Embolism.Diagnostics (Basel, Switzerland) · 2026Review
- Pulmonary Embolism in Antiphospholipid Syndrome (APS)-Where Are We and Where Are We Going?International journal of molecular sciences · 2026Review
- Thrombus aspiration andFrontiers in cardiovascular medicine · 2026Article
- Pulmonary Embolism in Acute Ischaemic Stroke: Evolving Evidence, Diagnostic Challenges, and a Novel Thromboinflammatory Axis Hypothesis.International journal of molecular sciences · 2025Review
- Management of Hemodynamic and Respiratory Instability and Anesthetic Approaches in Patients Undergoing Pulmonary Thrombectomy for Pulmonary Embolism.Journal of clinical medicine · 2025Article
- The latest in the management of pulmonary embolism.Breathe (Sheffield, England) · 2025Review
- Large-bore Aspiration Thrombectomy with the FlowTriever System for the Treatment of Pulmonary Embolism: A Large Single-Center Retrospective Analysis.Cardiovascular and interventional radiology · 2024Article
- Cutting-Edge Techniques and Drugs for the Treatment of Pulmonary Embolism: Current Knowledge and Future Perspectives.Journal of clinical medicine · 2024Review
- Catheter Interventions for Pulmonary Embolism: Mechanical Thrombectomy Versus Thrombolytics.Methodist DeBakey cardiovascular journal · 2024Review
- Navigating the Complexity of High-Risk Pulmonary Embolism-Is Mechanical Thrombectomy the Answer We Need?Journal of the Society for Cardiovascular Angiography & Interventions · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute mortality for high-risk, or massive, pulmonary embolism (PE) is almost 30% even when treated using advanced therapies. This analysis assessed the safety and effectiveness of mechanical thrombectomy (MT) for high-risk PE. Methods: The prospective, multicenter FlowTriever All-comer Registry for Patient Safety and Hemodynamics (FLASH) study is designed to evaluate real-world PE patient outcomes after MT with the FlowTriever System (Inari Medical). In this study, acute outcomes through 30 days were evaluated for the subset of patients with high-risk PE as determined by the sites and following European Society of Cardiology guidelines. An independent medical monitor adjudicated adverse events (AEs), including major AEs: device-related mortality, major bleeding, or intraprocedural device-related or procedure-related AEs. Results: Of the 799 patients in the US cohort, 63 (7.9%) were diagnosed with high-risk PE; 30 (47.6%) patients showed a systolic blood pressure <90 mm Hg, 29 (46.0%) required vasopressors, and 4 (6.3%) experienced cardiac arrest. The mean age of patients with high-risk PE was 59.4 ± 15.6 years, and 34 (54.0%) were women. At baseline, 45 (72.6%) patients were tachycardic, 18 (54.5%) showed elevated lactate levels of ≥2.5 mM, and 21 (42.9%) demonstrated depressed cardiac index of <2 L/min/m Conclusions: In this cohort of 63 patients with high-risk PE, MT was safe and effective, with no acute mortalities reported. Further prospective data are needed in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.